Comparison of Forced Expiratory Flow (FEF) 25-75% between Post-COVID-19 Patients with Different Severity at Universitas Gadjah Mada Academic Hospital
Downloads
Introduction: Shortness of breath is the most distressing long COVID-19 symptom associated with the decline of small airway function, as shown by a decrease in forced expiratory flow (FEF) 25-75% value in the spirometry test. This study aimed to compare FEF 25-75% values as a predictor of small airway disease between mild-moderate and severe-critical long COVID-19 patients.
Methods: This study used a prospective cohort design that included 24 post-hospitalized COVID-19 patients who came to the long COVID-19 clinic at Universitas Gadjah Mada Academic Hospital (UGM AH), Yogyakarta. The subjects were divided into mild-moderate and severe-critical groups based on the World Health Organization (WHO) classification. The subjects were tested for spirometry three months after the onset of COVID-19 symptoms. The comparison of both severity groups used the percent prediction of FEF 25-75% spirometry results. The value was interpreted as abnormal if the predicted FEF 25-75% value was below 65%.
Results: There were three (25%) and two (16.67%) subjects with FEF 25-75% predicted below normal values in the mild-moderate and severe-critical groups consecutively, which showed a decline in small airway function. This study showed no statistically significant differences (p-value = 0.882) between the means of FEF 25-75% predicted values of the two groups.
Conclusion: A small proportion of post-COVID-19 syndrome patients had small airway disease, and there were no statistical differences in small airway function between the groups.
(WHO) WHO. Living Guidance for Clinical Management of COVID-19. Geneva, https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-clinical-2021-2 (2021).
Prevention C for DC and. Post-COVID Conditions. CDC, https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Flong-term-effects.html (2021).
Burhan E. Long COVID: Diagnosis and Treatment of Respiratory Syndrome in Post COVID-19 Conditions. J Respirologi Indones 2022; 42: 250–256. [Journal]
Chen C, Haupert SR, Zimmermann L, et al. Global Prevalence of Post-Coronavirus Disease 2019 (COVID-19) Condition or Long COVID: A Meta-Analysis and Systematic Review. J Infect Dis 2022; 226: 1593–1607. [PubMed]
Nalbandian A, Sehgal K, Gupta A, et al. Post-Acute COVID-19 Syndrome. Nat Med 2021; 27: 601–615. [PubMed]
Fernández-de-Las-Peñas C, Palacios-Ceña D, Gómez-Mayordomo V, et al. Fatigue and Dyspnoea as Main Persistent Post-COVID-19 Symptoms in Previously Hospitalized Patients: Related Functional Limitations and Disability. Respiration 2022; 101: 132–141. [PubMed]
Aiyegbusi OL, Hughes SE, Turner G, et al. Symptoms, Complications and Management of Long COVID: A Review. J R Soc Med 2021; 114: 428–442. [Journal]
Elicker BM. What are the Long-term Pulmonary Sequelae of COVID-19 Infection? Radiology 2022; 304: 193–194. [Journal]
Staffolani S, Iencinella V, Cimatti M, et al. Long COVID-19 Syndrome as a Fourth Phase of SARS-CoV-2 Infection. Le Infez Med 2022; 30: 22–29. [PubMed]
McNulty W, Usmani OS. Techniques of Assessing Small Airways Dysfunction. Eur Clin Respir J; 1. Epub ahead of print 2014. [PubMed]
Bencana BNP. Peta Sebaran COVID-19, https://covid19.go.id/peta-sebaran (2022, accessed 3 May 2022).
Patria YN, Sabirin RM. COVID-19 Potentially Causes Long-Term Deterioration of Lung Function: A Systematic Review and Meta-Analysis. Med J Indones; 30. Epub ahead of print 30 December 2021. [Journal]
Liao X, Wang Y, He Z, et al. Three-Month Pulmonary Function and Radiological Outcomes in COVID-19 Survivors: A Longitudinal Patient Cohort Study. Open Forum Infect Dis 2021; 8: ofaa540. [PubMed]
Torres-Castro R, Vasconcello-Castillo L, Alsina-Restoy X, et al. Respiratory Function in Patients Post-Infection by COVID-19: A Systematic Review and Meta-Analysis. Pulmonology 2021; 27: 328–337. [PubMed]
Cortes-Telles A, Figueroa-Hurtado E, Ortiz-Farias DL, et al. Clinical Predictors of Lung Function in Patients Recovering from Mild COVID-19. BMC Pulm Med 2022; 22: 294. [PubMed]
Raji H, Shoushtari MH, Idani E, et al. Forced Expiratory Flow at 25-75% as a Marker for Airway Hyper Responsiveness in Adult Patients with Asthma-Like Symptoms. Tanaffos 2018; 17: 90–95. [PubMed]
Lukassen S, Chua RL, Trefzer T, et al. SARS-CoV-2 Receptor ACE2 and TMPRSS2 are Primarily Expressed in Bronchial Transient Secretory Cells. EMBO J 2020; 39: e105114. [PubMed]
Liew F, Efstathiou C, Openshaw PJM. Long COVID: Clues about Causes. Eur Respir J 2023; 2300409. [PubMed]
Yazji B, Voduc N, Mulpuru S, et al. Pulmonary Sequelae of SARS-CoV-2 Infection and Factors associated with Persistent Abnormal Lung Function at Six Months after Infection: Prospective Cohort Study. PLoS One 2022; 17: e0277624. [PubMed]
Chérrez-Ojeda I, Robles-Velasco K, Osorio M, et al. Small Airway Disease in Post-Acute Covid-19 Syndrome: A Non-Conventional Approach in Three Years Follow-Up of a Patient with Long COVID. 2023. Epub ahead of print 1 January 2023. [Journal]
Copyright (c) 2024 Muhammad Khidir, Siswanto Siswanto, Henda Ageng Rasena, Roihan Mohamad Iqbal, Rahmaningsih Mara Sabirin, Rakhmat Ari Wibowo, Sani Hadiyan Rasyid
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
1. The journal allows the author to hold the copyright of the article without restrictions.
2. The journal allows the author(s) to retain publishing rights without restrictions.
3. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution Share-Alike (CC BY-SA).
4. The Creative Commons Attribution Share-Alike (CC BY-SA) license allows re-distribution and re-use of a licensed work on the conditions that the creator is appropriately credited and that any derivative work is made available under "the same, similar or a compatible license”. Other than the conditions mentioned above, the editorial board is not responsible for copyright violation.